Building upon the remarkable in vitro tumor targeting ability of IR‐TAM@Alb, we proceeded to track the pharmacokinetics of IR‐TAM@Alb in vivo using a live animal imaging system within an MB49 tumor‐bearing model (Figure S17, Supporting Information). This evidence concerns the gene ALB and neoplasm.